DataM Intelligence Projects In-Silico Clinical Trials Market to Reach $6.39 Billion by 2033
The in-silico clinical trials market is projected to reach USD 6.39 billion by 2033, up from USD 3.95 billion in 2024, expanding at a compound annual growth rate of 5.5% between 2025 and 2033, announced in a press release by DataM Intelligence.
In-silico trials use computational modeling, virtual patient simulations, and AI-driven predictive systems to digitally test drug candidates, medical devices, and treatment protocols. These digital simulations complement laboratory and clinical studies by improving prediction accuracy and reducing experimental workloads.
The report highlights that pharmaceutical companies, medical device manufacturers, contract research organizations, and academic institutions are increasingly adopting in-silico trial platforms to modernize clinical development. The approach helps address challenges such as high development costs, regulatory delays, and patient recruitment difficulties, ultimately shortening the time to market for new therapies.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 17 Masimo Gets FDA Clearance for AFib Detection on Radius VSM Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflowsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Medical Image Analysis Software Market Forecast to Reach $6.3 Billion by 2031
Causal AI Market Forecast to Reach $761.4 Million by 2031
Laboratory Software Market Forecast to Reach $10.62 Billion by 2031
Insilico Medicine Opens AI Longevity Research Toolkit
Bain Says AI Needs $6 Trillion in Annual Revenue by 2031
Daily AI Brief: the AI news that matters, in your inbox.